.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

European committee recommends approval of glaucoma treatment

April 1, 2006

The Committee for Medicinal Products for Human Use (CHMP) recommended that the European Commission approve bimatoprost/timolol ophthalmic solution (Ganfort, Allergan) for treatment of glaucoma.

The Committee for Medicinal Products for Human Use (CHMP) recommended that the European Commission approve bimatoprost/timolol ophthalmic solution (Ganfort, Allergan) for treatment of glaucoma.

CHMP’s opinion is the basis for the European Commission approval. Allergan expects final approval in the second quarter of 2006.

The combination drug’s indication is for the reduction of IOP in patients with open-angle glaucoma or ocular hypertension, plus insufficient responsiveness to topical beta-blockers or prostaglandin analogues.